Annals of medicine and surgery (2012)|2025|Afridi Z et al.|2 citations
PMID: 40110282
A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
AIMS: This article aims to summarize the role of compounded incretin mimetics in clinical practice and in the context of drug shortages. METHODS: The Endocrine and Metabolism Practice and Research Network, a focused group of the American College of C…
Therapeutic proteins and peptides have revolutionized modern biomedicine, but their oral delivery is limited by gastrointestinal degradation and barriers. Small extracellular vesicles (sEVs), which are resistant to biochemical degradation and capable…
Obesity is the most prevalent condition in high-income nations, primarily associated with increased risk of diabetes, cardiovascular disease (CVD), hypertension, and hyperlipidemia. Lifestyle modifications are a key determinant in non-pharmacological…
Type 1 diabetes mellitus (T1D) is a chronic autoimmune disease caused by the immune-mediated destruction of insulin-producing pancreatic beta cells, resulting in the lifelong need for exogenous insulin. Over the last few years, overweight and obesity…
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) treat overweight or obesity with or without diabetes. This review aims to evaluate the effects of GLP-1 RAs on weight and cardiometabolic measures. This systematic review and meta-analysis of ra…
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory disease associated with obesity and metabolic dysregulation. Current therapies yield variable benefits and do not target metabolic drivers. Tirzepatide, a dual GLP-1/GIP receptor ago…
Tirzepatide could control postprandial hyperglycemia even in cases with diminished β-cell function. This finding gives new insight into the treatment of older patients with diabetes. However, tilzepatide does not replace basal insulin in cases with d…
Fifteen to forty% of patients experience recurrent weight gain (RWG) after metabolic bariatric surgery (MBS). Glucagon-like peptide receptor agonists (GLP-1 RAs) are effective treatments for obesity in nonsurgical patients. To assess the effects of s…
BACKGROUND AND AIMS: Obesity is a risk factor for relapsing inflammatory bowel disease. GLP-1 and dual GLP-1/GIP agonists may offer superior weight loss; however, their effect on inflammatory bowel disease remains unknown. In this study, we assessed…
Obesity management, whether lifestyle-based, pharmacological, or surgical, is frequently associated with gastrointestinal adverse effects (GI AEs) that may impact treatment adherence and patient quality of life. With the increasing use of incretin-ba…
The ground-breaking development of the incretin agonists by manipulation of the incretin system, including the gut hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), as well as the pancreatic hormone gluc…
BACKGROUND: Tirzepatide (TZP), a dual agonist of glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has recently been introduced in Italy for the treatment of obesity. Obesity is frequently associated with m…
In diabetic patients, treatment with GLP-1 (Glucagon-Like Peptide-1) and dual GLP-1/GIP (gastric inhibitory polypeptide) agonists, such as, respectively, semaglutide and tirzepatide, is effective in lowering blood sugar and reducing weight. However,…